Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
50
AUTL Quote, Financials, Valuation and Earnings
Last price:
$1.68
Seasonality move
:
-20.08%
Day range:
$1.63 - $1.68
52-week range:
$1.11 - $2.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.67x
P/B ratio:
2.23x
Volume:
754.7K
Avg. volume:
3.3M
1-year change:
-27.39%
Market cap:
$444.5M
Revenue:
$10.1M
EPS (TTM):
-$0.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
$27.5M | -$0.21 | 84624.25% | -288.08% | $9.52 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.2M | -$0.82 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$9M | $0.00 | -100% | -88.64% | $7.20 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
$1.67 | $9.52 | $444.5M | -- | $0.00 | 0% | 8.67x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.82 | $21.50 | $473.1M | -- | $0.00 | 0% | 16.67x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.63 | $17.94 | $2.2M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$2.31 | $7.20 | $367.3M | -- | $0.00 | 0% | 721.31x |
|
NCNA
NuCana Plc
|
$3.31 | $104.00 | $13.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 2.129 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 0.598 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Autolus Therapeutics Plc vs. Competitors
-
Which has Higher Returns AUTL or BCYC?
Bicycle Therapeutics Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of -503.67%. Autolus Therapeutics Plc's return on equity of -59.51% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About AUTL or BCYC?
Autolus Therapeutics Plc has a consensus price target of $9.52, signalling upside risk potential of 470.19%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 215.25%. Given that Autolus Therapeutics Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Autolus Therapeutics Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is AUTL or BCYC More Risky?
Autolus Therapeutics Plc has a beta of 2.013, which suggesting that the stock is 101.348% more volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.505%.
-
Which is a Better Dividend Stock AUTL or BCYC?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BCYC?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than Bicycle Therapeutics Plc quarterly revenues of $11.7M. Autolus Therapeutics Plc's net income of -$78.6M is lower than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 8.67x versus 16.67x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc8.67x -- $21.1M -$78.6M BCYCBicycle Therapeutics Plc16.67x -- $11.7M -$58.7M
-
Which has Higher Returns AUTL or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of --. Autolus Therapeutics Plc's return on equity of -59.51% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AUTL or BDRX?
Autolus Therapeutics Plc has a consensus price target of $9.52, signalling upside risk potential of 470.19%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 6662.41%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is AUTL or BDRX More Risky?
Autolus Therapeutics Plc has a beta of 2.013, which suggesting that the stock is 101.348% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock AUTL or BDRX?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BDRX?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Autolus Therapeutics Plc's net income of -$78.6M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 8.67x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc8.67x -- $21.1M -$78.6M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AUTL or MREO?
Mereo BioPharma Group Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of -2923.31%. Autolus Therapeutics Plc's return on equity of -59.51% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About AUTL or MREO?
Autolus Therapeutics Plc has a consensus price target of $9.52, signalling upside risk potential of 470.19%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $7.20 which suggests that it could grow by 211.76%. Given that Autolus Therapeutics Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe Autolus Therapeutics Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 MREOMereo BioPharma Group Plc6 0 0 -
Is AUTL or MREO More Risky?
Autolus Therapeutics Plc has a beta of 2.013, which suggesting that the stock is 101.348% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.376, suggesting its less volatile than the S&P 500 by 62.425%.
-
Which is a Better Dividend Stock AUTL or MREO?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or MREO?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Autolus Therapeutics Plc's net income of -$78.6M is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 8.67x versus 721.31x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc8.67x -- $21.1M -$78.6M MREOMereo BioPharma Group Plc721.31x -- -- -$7M
-
Which has Higher Returns AUTL or NCNA?
NuCana Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of --. Autolus Therapeutics Plc's return on equity of -59.51% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About AUTL or NCNA?
Autolus Therapeutics Plc has a consensus price target of $9.52, signalling upside risk potential of 470.19%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 628298.79%. Given that NuCana Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe NuCana Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 NCNANuCana Plc0 1 0 -
Is AUTL or NCNA More Risky?
Autolus Therapeutics Plc has a beta of 2.013, which suggesting that the stock is 101.348% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock AUTL or NCNA?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or NCNA?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than NuCana Plc quarterly revenues of --. Autolus Therapeutics Plc's net income of -$78.6M is lower than NuCana Plc's net income of -$378.9K. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 8.67x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc8.67x -- $21.1M -$78.6M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
